Autonomix Medical, Inc. AMIX
We are a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Our platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency ("RF") ablation, enabling a "sense, treat, verify" approach intended to improve the precision and consistency of nerve-targeted therapies.
The technology we have developed consists of a catheter-based system incorporating a proprietary microchip-enabled sensing architecture designed to detect low-amplitude neural signals from within the vascular system. By placing signal amplification and digitization at or near the point of detection, this approach is intended to reduce signal degradation and improve detection of neural activity compared to conventional systems. We believe this may enable more precise localization of target nerves and support targeted therapeutic intervention.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | — |
| R&D | $7.1M | $4.7M | $2.2M | $745.0K | — |
| SG&A | $9.9M | $6.9M | $5.2M | $1.2M | — |
| Total operating expenses | $17.0M | $11.6M | $12.0M | $2.0M | — |
| Operating income | -$17.0M | -$11.6M | -$12.0M | -$2.0M | — |
| Interest expense | $0 | $176.0K | $79.0K | $0 | — |
| Pre-tax income | -$16.7M | -$11.4M | -$15.4M | -$2.0M | — |
| Income tax | $0 | $0 | $0 | $0 | — |
| Net income | -$16.7M | -$11.4M | -$15.4M | -$2.0M | — |
| EPS, basic | -2.32 | -6.46 | -14.82 | -0.17 | — |
| Shares, diluted (wtd. avg.) | 7.2M | 1.8M | 1.0M | 12.0M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cash and equivalents | $7.0M | $9.1M | $8.6M | $865.0K | — |
| Total current assets | $7.6M | $9.6M | $9.4M | $865.0K | — |
| Property, plant and equipment | $19.0K | $21.0K | $16.0K | $0 | — |
| Total assets | $7.6M | $9.8M | $9.4M | $865.0K | — |
| Accounts payable | $700.0K | $676.0K | $492.0K | $173.0K | — |
| Total current liabilities | $1.7M | $1.7M | $777.0K | $221.0K | — |
| Total liabilities | $1.7M | $1.7M | $1.8M | $221.0K | — |
| Retained earnings | -$67.1M | -$50.4M | -$39.0M | -$23.5M | — |
| Total equity | $5.9M | $8.1M | $7.6M | $644.0K | $2.0M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$12.3M | -$8.3M | -$6.6M | -$1.9M | — |
| Depreciation and amortisation | $12.0K | $183.0K | $81.0K | $0 | — |
| Stock-based compensation | $529.0K | $1.6M | $618.0K | $0 | — |
| Capital expenditure | $10.0K | $14.0K | $19.0K | $0 | — |
| Investing cash flow | -$10.0K | -$14.0K | -$19.0K | $0 | — |
| Financing cash flow | $10.2M | $8.8M | $14.4M | $675.0K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001437749-26-020686.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — |
| Net income | — | -$2.0M | -$15.4M | -$11.4M | -$16.7M |
Recent filings and events
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Other event Item 8.01
- Material agreement signed Item 1.01
- Unregistered share sale Item 3.02
- Other event Item 8.01
- Other event Item 8.01
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Other event Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3841
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| SYK | STRYKER CORP | $117.81B | 36.6x | 11.2% |
| MMM | 3M CO | $89.46B | 28.9x | 1.5% |
| BSX | BOSTON SCIENTIFIC CORP | $66.22B | 23.6x | 19.9% |
| BDX | BECTON DICKINSON & CO | $54.18B | 34.2x | 8.2% |
| RMD | RESMED INC | $36.48B | 24.2x | 9.9% |
| DXCM | DEXCOM INC | $29.41B | 37.3x | 15.6% |
| MDLN | Medline Inc. | $29.20B | — | 11.5% |
| WST | WEST PHARMACEUTICAL SERVICES INC | $27.60B | 57.8x | 6.3% |